[go: up one dir, main page]

NO20001962D0 - Terapeutisk anvendelse av kinolinderivater - Google Patents

Terapeutisk anvendelse av kinolinderivater

Info

Publication number
NO20001962D0
NO20001962D0 NO20001962A NO20001962A NO20001962D0 NO 20001962 D0 NO20001962 D0 NO 20001962D0 NO 20001962 A NO20001962 A NO 20001962A NO 20001962 A NO20001962 A NO 20001962A NO 20001962 D0 NO20001962 D0 NO 20001962D0
Authority
NO
Norway
Prior art keywords
therapeutic use
quinoline derivatives
quinoline
derivatives
therapeutic
Prior art date
Application number
NO20001962A
Other languages
English (en)
Other versions
NO20001962L (no
Inventor
Zaid Jayyosi
Gerard M Mcgeehan
Michael F Kelley
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of NO20001962D0 publication Critical patent/NO20001962D0/no
Publication of NO20001962L publication Critical patent/NO20001962L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20001962A 1997-10-17 2000-04-14 Terapeutisk anvendelse av kinolinderivater NO20001962L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6231897P 1997-10-17 1997-10-17
US6590297P 1997-11-17 1997-11-17
PCT/US1998/021947 WO1999020275A1 (en) 1997-10-17 1998-10-16 Therapeutic uses of quinoline derivatives

Publications (2)

Publication Number Publication Date
NO20001962D0 true NO20001962D0 (no) 2000-04-14
NO20001962L NO20001962L (no) 2000-06-16

Family

ID=26742119

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20001962A NO20001962L (no) 1997-10-17 2000-04-14 Terapeutisk anvendelse av kinolinderivater
NO20003107A NO20003107L (no) 1997-10-17 2000-06-16 FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20003107A NO20003107L (no) 1997-10-17 2000-06-16 FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR

Country Status (17)

Country Link
US (1) US6376512B1 (no)
EP (1) EP1030665A4 (no)
JP (1) JP2001520193A (no)
KR (1) KR20010024533A (no)
CN (1) CN1302206A (no)
AP (1) AP2000001786A0 (no)
AU (1) AU9696198A (no)
BG (1) BG104432A (no)
BR (1) BR9814087A (no)
CA (1) CA2306825A1 (no)
EA (1) EA200000427A1 (no)
HU (1) HUP0101022A1 (no)
IL (1) IL135673A0 (no)
NO (2) NO20001962L (no)
OA (1) OA11371A (no)
PL (1) PL344977A1 (no)
WO (1) WO1999020275A1 (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU74701A (sh) * 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati tri-aril kiseline kao ligandi ppar receptora
ES2287016T3 (es) 1999-04-28 2007-12-16 Sanofi-Aventis Deutschland Gmbh Derivados de diaril-acido como ligandos del receptor ppar.
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU7073400A (en) * 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP2001261654A (ja) * 2000-03-21 2001-09-26 Mitsui Chemicals Inc キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
AU6118001A (en) * 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CA2433573A1 (en) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Alkanoic acid derivatives, process for their production and use thereof
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
SI1353696T1 (sl) 2001-01-26 2007-04-30 Schering Corp Kombinacije aktivatorja(-ev) peroksisomskega proliferatorja aktivirajocega receptorja (PPAR) in inhibitorja(-ev) absorpcije sterola in oblike zdravljenja za vaskularne indikacije
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
EP1461323B1 (en) * 2001-06-12 2013-10-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2003016265A1 (fr) * 2001-08-17 2003-02-27 Eisai Co., Ltd. Compose cyclique et agoniste du recepteur ppar
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
SE0201937D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
ES2299702T3 (es) 2002-06-20 2008-06-01 Astrazeneca Ab Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.
JP4579681B2 (ja) 2002-07-09 2010-11-10 ブリストル−マイヤーズ スクイブ カンパニー 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
JP2006508189A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 自己免疫障害の処置のためのコレステロール吸収インヒビター
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN100482649C (zh) * 2003-09-17 2009-04-29 诺瓦提斯公司 有机化合物
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
WO2005105726A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
JP5052511B2 (ja) 2005-06-30 2012-10-17 ハイ ポイント ファーマシューティカルズ，エルエルシー Ｐｐａｒデルタ活性化因子としてのフェノキシ酢酸
CA2621406A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
EP1979311B1 (en) 2005-12-22 2012-06-13 High Point Pharmaceuticals, LLC Phenoxy acetic acids as ppar delta activators
JP2009529512A (ja) 2006-03-09 2009-08-20 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 新規な化合物、それらの製造法、及び使用法
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
NZ588374A (en) 2008-04-30 2012-11-30 Wellstat Therapeutics Corp Tetrazole compounds for reducing uric acid
CN102573473B (zh) 2009-06-09 2015-05-27 加利福尼亚资本权益有限责任公司 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物
EP2440053A4 (en) 2009-06-09 2012-10-31 California Capital Equity Llc BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
CA2765030C (en) 2009-06-09 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
EP2593431B1 (en) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
WO2012007877A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
EP2593427B1 (en) 2010-07-12 2014-12-24 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP3129345B1 (en) * 2014-04-06 2023-03-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof
MX2023001448A (es) * 2020-08-04 2023-06-22 Prec Bio Therapeutics S R L Compuestos de quinolina como moduladores selectivos y/o duales de los receptores del acido biliar y los receptores del cisteinil-leucotrieno.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4920130A (en) * 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
HU219565B (hu) * 1993-11-29 2001-05-28 Merrell Pharmaceuticals Inc. IL-1 hatást inhibiáló új benzolszulfonil-imin-származékok és alkalmazásuk
EP0709377B1 (en) * 1994-10-27 1999-09-29 Asahi Glass Company Ltd. Process for producing quinolin-2-yl benzoic acid compounds
ATE262899T1 (de) * 1996-01-02 2004-04-15 Aventis Pharma Inc Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen

Also Published As

Publication number Publication date
EP1030665A1 (en) 2000-08-30
IL135673A0 (en) 2001-05-20
BG104432A (bg) 2000-12-29
HUP0101022A1 (hu) 2001-10-28
KR20010024533A (ko) 2001-03-26
PL344977A1 (en) 2001-11-19
AP2000001786A0 (en) 2000-04-16
NO20001962L (no) 2000-06-16
AU9696198A (en) 1999-05-10
WO1999020275A1 (en) 1999-04-29
EA200000427A1 (ru) 2001-02-26
CA2306825A1 (en) 1999-04-29
EP1030665A4 (en) 2002-11-27
BR9814087A (pt) 2000-10-03
US6376512B1 (en) 2002-04-23
CN1302206A (zh) 2001-07-04
JP2001520193A (ja) 2001-10-30
OA11371A (en) 2004-01-28
NO20003107D0 (no) 2000-06-16
NO20003107L (no) 2000-07-26

Similar Documents

Publication Publication Date Title
NO20001962D0 (no) Terapeutisk anvendelse av kinolinderivater
NO20001628L (no) Polymerderivater av kamptoteciner
IS5245A (is) Lyfjablanda úr ómeprasól
IS5760A (is) Meðferðarlegar bíarýl afleiður
BR9507179A (pt) Derivados de 3-aril-4-hidróxi-delta3-dihidrotiofena
ATE289994T1 (de) Chinolin-derivate
ID18679A (id) Penggunaan terapi lanjutan
FI964193A0 (fi) Puriinien valmistaminen
NO20015738D0 (no) Terapeutisk bruk av melatonin
NO996545L (no) Behandling av aluminiumslagg
FI971527L (fi) Indolijohdannaisten käyttö erilaisten sairauksien hoitoon
FI963532A (fi) Kinoliini-3-karboksamidiyhdisteiden uusi käyttö
FI963531A (fi) Kinoliini-3-karboksamidiyhdisteiden uusi käyttö
NO992726D0 (no) Ny terapeutisk anvendelse av et tienylsykloheksylaminderivat
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
NO20016030D0 (no) Derivater av 4'-demykarosyl-8a-aza-8a-homotylosin
NO991148L (no) Fremstilling av 1-butyl-4-piperidinyl-metylamin
ID24439A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
FI974235A0 (fi) Ny bestaemningsmetod
BR9704770A (pt) Derivados de 1-carba-(detia)-cefalosporina
ID24521A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
NO995269D0 (no) Anvendelse av immunmodulerende midler
ZA989465B (en) Therapeutic uses of quinoline derivatives.
NO974458D0 (no) Fremstilling av cis-4-O-beskyttede-2-cyklopentenolderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application